Subjects
CRC
Participants of CO.20 were from Australia and Canada and had histologically confirmed, chemotherapy‐refractory, metastatic CRC that was mostly KRAS‐wildtype. The CRC patients were aged 18 years or older and did not have a serious concurrent illness. From the years 2008–2011, CRC patients were 1:1 randomly assigned to the experimental Cetuximab+Brivanib treatment arm or the standard Cetuximab +placebo treatment arm.